Nomura Asset Management Co. Ltd. Acquires 1,885 Shares of Stryker Co. (NYSE:SYK)

Nomura Asset Management Co. Ltd. boosted its position in Stryker Co. (NYSE:SYK - Free Report) by 1.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 148,892 shares of the medical technology company's stock after acquiring an additional 1,885 shares during the period. Nomura Asset Management Co. Ltd.'s holdings in Stryker were worth $53,609,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SYK. New Age Alpha Advisors LLC purchased a new position in shares of Stryker in the fourth quarter valued at $1,063,000. Providence Capital Advisors LLC purchased a new position in Stryker during the 4th quarter valued at about $4,902,000. Norges Bank bought a new stake in shares of Stryker during the fourth quarter valued at about $1,710,744,000. Rockbridge Investment Management LCC purchased a new stake in shares of Stryker in the fourth quarter worth about $385,000. Finally, AssuredPartners Investment Advisors LLC bought a new position in shares of Stryker in the fourth quarter valued at approximately $407,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. Wells Fargo & Company raised their price target on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Citigroup reissued a "buy" rating and set a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Finally, Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $421.90.

Remove Ads

Stryker Trading Up 0.3 %

Stryker stock traded up $1.11 during trading hours on Wednesday, reaching $374.41. The company had a trading volume of 541,611 shares, compared to its average volume of 1,441,690. The firm has a market cap of $142.91 billion, a price-to-earnings ratio of 48.25, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a 50-day moving average price of $383.41 and a 200 day moving average price of $374.43.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business earned $3.46 EPS. Equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.50% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.